Mark For: PROBUPHINE® trademark registration is intended to cover the categories of pharmaceuticals, namely, implantable drug delivery system comprised primarily of sustained release drugs for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases. [all]
Status
2022-08-22 UTC
DEAD REGISTRATION Cancelled Invalidated
The trademark application was registered, but subsequently it was cancelled or invalidated and removed from the registry.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
Yes
Intent To Use
No
Filed ITU
Yes
44D Filed
No
44E Current
No
66A Current
No
Current Basis
No
No Basis
No
Cancellation Code
2
Attorney Name
Rosemary S. Tarlton
Attorney Docket Number
30414-24007
Law Office Assigned
L50
Employee Name
JOHNSON, AISHA CLARKE
Timeline
2001-07-06
Application Filed
2002-06-18
Published
2002-06-18
Published for Opposition
2003-04-00
Date of First Use
2003-04-01
Date of First Use
2003-04-01
Date of Use In Commerce
2003-12-30
Trademark Registered
2004-01-12
Location: FILE REPOSITORY (FRANCONIA)
2010-08-07
Cancelled
2010-08-07
Status: Dead/Cancelled
2010-08-07
Status: Registration cancelled because registrant did not file an acceptable declaration under Section 8. To view all documents in this
ROSEMARY S. TARLTON MORRISON & FOERSTER LLP 425 MARKET ST FL 30 SAN FRANCISCO CA 94105-2482
Good, Services, and Codes
(CANCELLED) IC 005. US 006 018 044 046 051 052. G & S: PHARMACEUTICALS, NAMELY, IMPLANTABLE DRUG DELIVERY SYSTEM COMPRISED PRIMARILY OF SUSTAINED RELEASE DRUGS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, CANCER AND OTHER SERIOUS AND LIFE-THREATENING DISEASES. FIRST USE: 20030400. FIRST USE IN COMMERCE: 20030400
International Codes:
5
U.S. Codes:
006,018,044,046,051,052
Type Code
Type
GS0051
PHARMACEUTICALS, NAMELY, IMPLANTABLE DRUG DELIVERY SYSTEM COMPRISED PRIMARILY OF SUSTAINED RELEASE DRUGS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, CANCER AND OTHER SERIOUS AND LIFE-THREATENING DISEASES
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.